BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, Volovat C, Grierosu I, Ionescu T, Jalloul W, Ghizdovat V, Gherasim R, Volovat S, Wang F, Fu J, Moscalu R, Matovic M, Stefanescu C. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. J Pers Med 2021;11:1042. [PMID: 34683183 DOI: 10.3390/jpm11101042] [Reference Citation Analysis]
2 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R, Khosla D. 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Glob Oncol 2021;7:1167-75. [PMID: 34288699 DOI: 10.1200/GO.21.00103] [Reference Citation Analysis]
3 Chauhan A, Das S, Miller R, Luque L, Cheuvront SN, Cloud J, Tarter Z, Siddiqui F, Ramirez RA, Anthony L. Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? BMC Cancer 2021;21:580. [PMID: 34016080 DOI: 10.1186/s12885-021-08315-4] [Reference Citation Analysis]
4 Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O. Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method. J Med Imaging (Bellingham) 2020;7:012704. [PMID: 31824983 DOI: 10.1117/1.JMI.7.1.012704] [Reference Citation Analysis]
5 Bilski M, Mertowska P, Mertowski S, Sawicki M, Hymos A, Niedźwiedzka-Rystwej P, Grywalska E. The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers (Basel) 2021;14:177. [PMID: 35008341 DOI: 10.3390/cancers14010177] [Reference Citation Analysis]
6 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2021. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Reference Citation Analysis]
7 Gulpinar B, Peker E, Kul M, Elhan AH, Haliloglu N. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features? Abdom Radiol (NY) 2019;44:2147-55. [PMID: 30863999 DOI: 10.1007/s00261-019-01963-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, Dakhel Plaza S, Nadal L, Gloger A, Schmidt E, Biancofiore I, Donckele EJ, Samain F, Neri D, Cazzamalli S. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A 2021;118:e2101852118. [PMID: 33850024 DOI: 10.1073/pnas.2101852118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gulpinar B, Peker E, Soydal C, Araz M, Elhan AH. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings. Br J Radiol 2020;93:20190735. [PMID: 31922897 DOI: 10.1259/bjr.20190735] [Reference Citation Analysis]
10 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ipek Işıkcı N, Abuqbeitah M, Demir M. The Interference of Gamma Rays With Bone Mineral Density Measurements in 177Lu-PSMA and DOTATATE Therapy. J Clin Densitom 2021:S1094-6950(21)00073-1. [PMID: 34654625 DOI: 10.1016/j.jocd.2021.08.003] [Reference Citation Analysis]
12 Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Reference Citation Analysis]
13 Satapathy S, Bhattacharya A, Sood A, Kapoor R, Gupta R, Sood A, Sharma P, Khosla D, Mittal BR. Hematological Markers as Predictors of Treatment Outcomes with Lu-177 DOTATATE in Patients with Advanced Neuroendocrine Tumors. Cancer Biother Radiopharm 2021. [PMID: 34185573 DOI: 10.1089/cbr.2021.0053] [Reference Citation Analysis]
14 Kamarul Bahrin MH, Hagag R, Ali A, Yahia S, Armstrong R. Benign Oesophageal Stricture and Chronic Diarrhoea As Atypical Presenting Symptoms of an Advanced Metastatic Pancreatic Gastrinoma: A Case Report and Review of Literature. Cureus 2021;13:e16593. [PMID: 34447640 DOI: 10.7759/cureus.16593] [Reference Citation Analysis]
15 Dicitore A, Saronni D, Gaudenzi G, Carra S, Cantone MC, Borghi MO, Persani L, Vitale G. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines. J Endocrinol Invest 2021. [PMID: 34128215 DOI: 10.1007/s40618-021-01609-1] [Reference Citation Analysis]
16 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clin Nucl Med 2020;45:e393-9. [PMID: 32604121 DOI: 10.1097/RLU.0000000000003170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
18 Sanjuan-Sanjuan A, Alors-Perez E, Sanchez-Frías M, Dean-Ferrer A, Gahete MD, Heredero-Jung S, Luque RM. Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma. Cancers (Basel) 2021;13:4828. [PMID: 34638313 DOI: 10.3390/cancers13194828] [Reference Citation Analysis]
19 Bergsten J, Flachskampf FA, Lundin L, Öhagen P, Albåge A. A 33-year follow-up after valvular surgery for carcinoid heart disease. Eur Heart J Cardiovasc Imaging 2021:jeab049. [PMID: 33899077 DOI: 10.1093/ehjci/jeab049] [Reference Citation Analysis]
20 Tawfik B, Ray D, Moynihan M, Princic N. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. J Med Econ 2021;24:1337-45. [PMID: 34763589 DOI: 10.1080/13696998.2021.2005374] [Reference Citation Analysis]
21 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
22 Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 2020;12:E1437. [PMID: 32429294 DOI: 10.3390/nu12051437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Muscogiuri G, Barrea L, Campolo F, Sbardella E, Sciammarella C, Tarsitano MG, Bottiglieri F, Colao A, Faggiano A. Ketogenic diet: a tool for the management of neuroendocrine neoplasms? Crit Rev Food Sci Nutr 2020;:1-11. [PMID: 33938778 DOI: 10.1080/10408398.2020.1832955] [Reference Citation Analysis]
24 Caruso G, Sassu CM, Tomao F, Di Donato V, Perniola G, Fischetti M, Benedetti Panici P, Palaia I. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions. Crit Rev Oncol Hematol 2021;162:103344. [PMID: 33933568 DOI: 10.1016/j.critrevonc.2021.103344] [Reference Citation Analysis]
25 Rosenbaum MW, Gonzalez RS. Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology 2021;78:148-61. [PMID: 33382497 DOI: 10.1111/his.14244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]